Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1071MR)

This product GTTS-WQ1071MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1071MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8738MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ12045MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ14869MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ8867MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3529MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ14287MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ2399MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ5879MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW